Assyro AI

FDA Orange Book · active-ingredient family

Diatrizoate meglumine; diatrizoate sodium

Diatrizoate meglumine; diatrizoate sodium is approved as 4 brand and 11 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:MD-76R · NDA 019292

4

Brand (NDA)

11

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · injectable, solution

ProductApplicantApplicationTEApproved
MD-76RRLDLIEBEL-FLARSHEIMNDA 019292Sep 29, 1989
RENOGRAFIN-76RLD×4BRACCONDA 010040Approved Prior to Jan 1, 1982
GASTROGRAFINRLDBRACCONDA 011245AAApproved Prior to Jan 1, 1982
HYPAQUE-M,75%×2GE HEALTHCARENDA 010220Approved Prior to Jan 1, 1982

Generic (ANDA) products (11)

ProductApplicantApplicationTEApproved
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUMANNORA PHARMAANDA 215049AANov 17, 2023
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUMANDA REPOSITORYANDA 214201AAJun 27, 2022
RENOCAL-76BRACCOANDA 089347Jun 01, 1988
DIATRIZOATE-60INTL MEDICATIONANDA 088166Jun 17, 1983
ANGIOVIST 292BAYER HLTHCAREANDA 087724Sep 23, 1982
ANGIOVIST 370BAYER HLTHCAREANDA 087723Sep 23, 1982
GASTROVISTBAYER HLTHCAREANDA 087728Sep 23, 1982
HYPAQUE-76GE HEALTHCAREANDA 086505Approved Prior to Jan 1, 1982
MD-60MALLINCKRODTANDA 087074Approved Prior to Jan 1, 1982
MD-76MALLINCKRODTANDA 087073Approved Prior to Jan 1, 1982
MD-GASTROVIEWLIEBEL-FLARSHEIMANDA 087388AAApproved Prior to Jan 1, 1982

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Diatrizoate meglumine; diatrizoate sodium — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.